Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

CVS Health (CVS) Gets a Buy from Bernstein

Tipranks - Tipranks - Wed Apr 8, 6:42AM CDT

In a report released yesterday, Lance Wilkes from Bernstein assigned a Buy rating to CVS Health, with a price target of $94.00. The company’s shares closed yesterday at $73.28.

Easter Sale - 70% Off TipRanks

Wilkes covers the Healthcare sector, focusing on stocks such as Cigna, Centene, and CVS Health. According to TipRanks, Wilkes has an average return of -8.7% and a 32.67% success rate on recommended stocks.

Currently, the analyst consensus on CVS Health is a Strong Buy with an average price target of $96.33, implying a 31.45% upside from current levels. In a report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $105.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on CVS Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $105.69 billion and a net profit of $2.94 billion. In comparison, last year the company earned a revenue of $97.71 billion and had a net profit of $1.64 billion

Read More on CVS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).